NT5E and bladder transitional cell carcinoma: Other targets for immunotherapy being explored include CD73, an immune-modulator recently identified as potential target that is part of an ongoing phase 1b clinical trial testing the combination of Pembrolizumab and anti-CD73 in a variety of malignancies, including bladder urothelial carcinomas [63].